Media matters: culture medium-dependent hypervariable phenotype of mesenchymal stromal cells

Joan C. Fitzgerald,Georgina Shaw,J. Mary Murphy,Frank Barry
DOI: https://doi.org/10.1186/s13287-023-03589-w
2023-12-13
Stem Cell Research & Therapy
Abstract:Despite a long history of investigation and sustained efforts in clinical testing, the number of market authorisations for mesenchymal stromal cell (MSC) therapies remains limited, with none approved by the United States Food and Drug Administration. Several barriers are impeding the clinical progression of MSC therapies, to the forefront of these is a lack of standardised manufacturing protocols which is further compounded by an absence of biologically meaningful characterisation and release assays. A look at clinical trial registries demonstrates the diversity of MSC expansion protocols with variabilities in cell source, isolation method and expansion medium, among other culture variables, making it extraordinarily difficult to compare study outcomes. Current identification and characterisation standards are insufficient; they are not specific to MSCs and do not indicate cell function or therapeutic action.
cell biology,medicine, research & experimental,cell & tissue engineering
What problem does this paper attempt to address?